Latest & greatest articles for asthma

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on asthma or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on asthma and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for asthma

1021. Advising parents of asthmatic children on passive smoking: randomised controlled trial. Full Text available with Trip Pro

Advising parents of asthmatic children on passive smoking: randomised controlled trial. To investigate whether parents of asthmatic children would stop smoking or alter their smoking habits to protect their children from environmental tobacco smoke.Randomised controlled trial.Tayside and Fife, Scotland.501 families with an asthmatic child aged 2-12 years living with a parent who smoked.Parents were told about the impact of passive smoking on asthma and were advised to stop smoking or change (...) % confidence interval (-0.86 to 0.48). Overall, 98% of parents in both groups still smoked at follow up. However, there was a non-significant tendency for parents in the intervention group to report smoking more at follow up and to having a reduced desire to stop smoking.A brief intervention to advise parents of asthmatic children about the risks from passive smoking was ineffective in reducing their children's exposure to environmental tobacco smoke. The intervention may have made some parents less

1999 BMJ Controlled trial quality: uncertain

1022. Effects of writing about stressful experiences on symptom reduction in patients with asthma or rheumatoid arthritis: a randomized trial. (Abstract)

Effects of writing about stressful experiences on symptom reduction in patients with asthma or rheumatoid arthritis: a randomized trial. Nonpharmacological treatments with little patient cost or risk are useful supplements to pharmacotherapy in the treatment of patients with chronic illness. Research has demonstrated that writing about emotionally traumatic experiences has a surprisingly beneficial effect on symptom reports, well-being, and health care use in healthy individuals.To determine (...) if writing about stressful life experiences affects disease status in patients with asthma or rheumatoid arthritis using standardized quantitative outcome measures.Randomized controlled trial conducted between October 1996 and December 1997.Outpatient community residents drawn from private and institutional practice.Volunteer sample of 112 patients with asthma (n = 61) or rheumatoid arthritis (n = 51) received the intervention; 107 completed the study, 58 in the asthma group and 49 in the rheumatoid

1999 JAMA Controlled trial quality: uncertain

1023. Clustered randomised trial of an intervention to improve the management of asthma: Greenwich asthma study. Full Text available with Trip Pro

Clustered randomised trial of an intervention to improve the management of asthma: Greenwich asthma study. To evaluate the effectiveness of an asthma resource centre in improving treatment and quality of life for asthmatic patients.Community based randomised controlled trial.41 general practices in Greenwich with a practice nurse.All registered patients aged 15-50 years.Nurse specialists in asthma who educated and supported practice nurses, who in turn educated patients in the management (...) of asthma according to the British Thoracic Society's guidelines.Quality of life of asthmatic patients, attendance at accident and emergency departments, admissions to local hospitals, and steroid prescribing by general practitioners.Of 24 400 patients randomly selected and surveyed in 1993, 12 238 replied; 1621 were asthmatic of whom 1291 were sent a repeat questionnaire in 1996 and 780 replied. Of 24 400 patients newly surveyed in 1996, 10 783 (1616 asthmatic) replied. No evidence was found

1999 BMJ Controlled trial quality: predicted high

1024. Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group. (Abstract)

Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group. Immune responses mediated by IgE are important in the pathogenesis of allergic asthma. A recombinant humanized monoclonal antibody (rhuMAb-E25) forms complexes with free IgE and blocks its interaction with mast cells and basophils. We studied the efficacy of rhuMab-E25 as a treatment for moderate-to-severe allergic asthma.After a 4-week run-in period, we randomly assigned 317 subjects (age range, 11 to 50 (...) of corticosteroids they had received before enrollment. During the following eight weeks, the doses of corticosteroids were tapered in an effort to discontinue this therapy. The primary outcome measure was an improvement in the asthma symptom score at 12 weeks, according to a 7-point scale, in which a score of 1 indicated no symptoms and a score of 7 the most severe symptoms.A total of 106 subjects were assigned to receive a high dose of rhuMAb-E25, 106 were assigned to receive a low dose, and 105 were assigned

1999 NEJM Controlled trial quality: uncertain

1025. Inhaled budesonide in addition to oral corticosteroids to prevent asthma relapse following discharge from the emergency department: a randomized controlled trial. (Abstract)

Inhaled budesonide in addition to oral corticosteroids to prevent asthma relapse following discharge from the emergency department: a randomized controlled trial. Relapses of acute asthma following emergency department (ED) discharge can be reduced with systemic corticosteroid treatment. However, whether inhaled corticosteroids (ICSs) provide additional benefit is not known. Objective To determine whether the addition of ICSs to oral corticosteroid treatment would reduce relapses in patients (...) with acute asthma discharged from the ED.Placebo-controlled, double-blind, randomized clinical trial conducted in a community teaching hospital ED in Canada between November 1995 and September 1997, with a 21-day follow-up.A total of 1006 consecutive patients aged 16 to 60 years presented to the ED with acute asthma; after excluding those using oral and/or inhaled corticosteroids as well as those meeting other exclusion criteria, 188 were included in the study.Patients were discharged with a nontapering

1999 JAMA Controlled trial quality: predicted high

1026. Randomised, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients. Full Text available with Trip Pro

Randomised, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients. To determine the ability of montelukast, a leukotriene receptor antagonist, to allow tapering of inhaled corticosteroids in clinically stable asthmatic patients.Double blind, randomised, placebo controlled, parallel group study. After a single blind placebo run in period, during which (at most) two inhaled corticosteroids dose decreases (...) occurred, qualifying, clinically stable patients were allocated randomly to receive montelukast (10 mg tablet) or matching placebo once daily at bedtime for up to 12 weeks.23 academic asthma centres in United States, Canada, and Europe.226 clinically stable patients with chronic asthma receiving high doses of inhaled corticosteroids (113 randomised to montelukast and 113 to placebo).Every 2 weeks, the inhaled corticosteroids dose was tapered, maintained, or increased (rescue) based on a standardised

1999 BMJ Controlled trial quality: predicted high

1027. Home-made spacers for bronchodilator therapy in children with acute asthma: a randomised trial. (Abstract)

Home-made spacers for bronchodilator therapy in children with acute asthma: a randomised trial. A metered-dose inhaler (MDI) with spacer is the best way to deliver bronchodilator therapy for treatment of acute asthma. In developing countries, commercially produced spacers are generally unavailable or too costly. We tested the efficacy of home-made spacers (500 mL plastic bottle, polystyrene cup) compared with a conventional spacer for delivery of a beta2 agonist via MDI for children with acute (...) asthma.We studied children aged 5 to 13 years with acute asthma, stratified into those with mild airways obstruction (peak expiratory flow [PEF] 60-79% of predicted value) or moderate to severe airways obstruction (PEF 20-59% of predicted value). A beta2 agonist (fenoterol hydrobromide) was given via MDI and one of four randomly assigned spacers (conventional spacer, sealed 500 mL plastic bottle, unsealed 500 mL bottle, 200 mL polystyrene cup). Clinical score, pulmonary function tests, and oximetry were

1999 Lancet Controlled trial quality: uncertain

1028. Cost effectiveness of fluticasone propionate and flunisolide in the treatment of corticosteroid-naive patients with moderate asthma

; Androstadienes /economics /therapeutic use; Anti-Asthmatic Agents /economics /therapeutic use; Asthma /drug therapy /economics; Cost-Benefit Analysis; Double-Blind Method; Female; Fluocinolone Acetonide /analogs & Germany; Glucocorticoids /therapeutic use; Humans; Male; Middle Aged; Prospective Studies; Research Support, Non-U.S. Gov't; derivatives /economics /therapeutic use AccessionNumber 21999008330 Date bibliographic record published 31/08/2000 Date abstract record published 31/08/2000 NHS Economic (...) Cost effectiveness of fluticasone propionate and flunisolide in the treatment of corticosteroid-naive patients with moderate asthma Cost effectiveness of fluticasone propionate and flunisolide in the treatment of corticosteroid-naive patients with moderate asthma Cost effectiveness of fluticasone propionate and flunisolide in the treatment of corticosteroid-naive patients with moderate asthma Volmer T, Kielhorn A, Weber H H, Wiessmann K J Record Status This is a critical abstract of an economic

1999 NHS Economic Evaluation Database.

1029. Empirically supported treatments of disease-related symptoms in pediatric psychology: asthma, diabetes, and cancer

Empirically supported treatments of disease-related symptoms in pediatric psychology: asthma, diabetes, and cancer Empirically supported treatments of disease-related symptoms in pediatric psychology: asthma, diabetes, and cancer Empirically supported treatments of disease-related symptoms in pediatric psychology: asthma, diabetes, and cancer McQuaid E L, Nassau J H Authors' objectives To review empirical studies of psychological treatments for: 1. Reducing physical symptoms in children (...) and adolescents with asthma. 2. Improving glycaemic control in children and adolescents with diabetes. 3. Reducing chemotherapy side-effects in children and adolescents with cancer. Searching MEDLINE and PsycLIT were searched from 1970 using the search terms 'asthma', 'diabetes' or 'cancer' combined with phrases relating to psychological treatments, e.g. treatment, intervention, therapy, relaxation, biofeedback. In addition, reference lists of retrieved articles were examined for other relevant publications

1999 DARE.

1030. The long-term effects of pulmonary rehabilitation in patients with asthma and chronic obstructive pulmonary disease: a research synthesis

The long-term effects of pulmonary rehabilitation in patients with asthma and chronic obstructive pulmonary disease: a research synthesis The long-term effects of pulmonary rehabilitation in patients with asthma and chronic obstructive pulmonary disease: a research synthesis The long-term effects of pulmonary rehabilitation in patients with asthma and chronic obstructive pulmonary disease: a research synthesis Cambach W, Wagenaar R C, Koelman T W, van Keimpema A R, Kemper H C Authors (...) ' objectives To evaluate the long-term effects of pulmonary rehabilitation in patients with asthma and chronic obstructive pulmonary disease. Searching Index Medicus and MEDLINE were searched over the last 45 years using the following keywords: "pulmonary"; "obstructive"; "rehabilitation"; and "exercise". Current Contents was searched routinely. Cross-referencing in studies and reviews was examined. Articles not written in English, Dutch or German and abstracts were excluded. Study selection Study designs

1999 DARE.

1031. Effect of inhaled corticosteroids on bronchial responsiveness in patients with "corticosteroid naive" mild asthma: a meta-analysis

Effect of inhaled corticosteroids on bronchial responsiveness in patients with "corticosteroid naive" mild asthma: a meta-analysis Effect of inhaled corticosteroids on bronchial responsiveness in patients with "corticosteroid naive" mild asthma: a meta-analysis Effect of inhaled corticosteroids on bronchial responsiveness in patients with "corticosteroid naive" mild asthma: a meta-analysis van Grunsven P M, van Schayck C P, Molema J, Akkermans R P, van Weel C Authors' objectives To assess (...) the effects of inhaled corticosteroids on bronchial hyperresponsiveness (BHR) in patients with corticosteroid naive asthma by conventional meta-analysis. Searching MEDLINE (January 1966-June 1998) was searched, and the search terms were provided. The reference lists of the retrieved articles were also checked for additional references. Study selection Study designs of evaluations included in the review Only randomised controlled studies with a duration of at least two weeks were included. Specific

1999 DARE.

1032. The effects of antireflux surgery on asthmatics with gastroesophageal reflux Full Text available with Trip Pro

The effects of antireflux surgery on asthmatics with gastroesophageal reflux The effects of antireflux surgery on asthmatics with gastroesophageal reflux The effects of antireflux surgery on asthmatics with gastroesophageal reflux Field SK, Gelfand GA, McFadden SD Authors' objectives To review the available literature on the effects of antireflux surgery in asthma. Searching MEDLINE (1966-August 1998) was searched using the following terms: 'lung disease', 'asthma', and 'pulmonary function (...) antireflux surgery were included. Ten of the studies included data on ten or fewer than ten patients, two were only published as abstracts and asthmatic data could not be separated from non-asthmatic data in four studies. Sixteen studies were conducted in adults only (or mostly adults), five in children only, one in all ages and one included only infants and children. Overall, 173/192 patients showed an improvement in GER symptoms, 296/376 showed an improvement in asthma symptoms, 177/201 showed

1999 DARE.

1033. A meta-analysis of the effects of ipratropium bromide in adults with acute asthma

A meta-analysis of the effects of ipratropium bromide in adults with acute asthma A meta-analysis of the effects of ipratropium bromide in adults with acute asthma A meta-analysis of the effects of ipratropium bromide in adults with acute asthma Rodrigo G, Rodrigo C, Burschtin O Authors' objectives To determine whether inhaled ipratropium bromide provides additional benefits to adults with acute asthma, who are being treated with beta-agonists in an emergency department. Searching MEDLINE (...) was searched from 1978 to April 1999 using the following MeSH terms: 'N-isopropylatropine' or 'ipratropium bromide', and 'adult', 'acute asthma' or status asthmaticus'. Searches of Current Contents, the Science Citation Index, and review articles were also performed. Studies were limited to those published in the English language. Details of additional published and unpublished studies were obtained by contacting experts (pulmonologists and emergency physicians) and the manufacturer of ipratropium bromide

1999 DARE.

1034. Cost effectiveness analysis of inhaled anticholinergics for acute childhood and adolescent asthma

Cost effectiveness analysis of inhaled anticholinergics for acute childhood and adolescent asthma Cost effectiveness analysis of inhaled anticholinergics for acute childhood and adolescent asthma Cost effectiveness analysis of inhaled anticholinergics for acute childhood and adolescent asthma Lord J, Ducharme F M, Stamp R J, Littlejohns P, Churchill R Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains (...) a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The health intervention examined in the study was the addition of inhaled anticholinergics to beta-2 agonists for the treatment of acute childhood and adolescent asthma. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population comprised children and adolescents

1999 NHS Economic Evaluation Database.

1035. A randomized controlled trial of a pediatric asthma outreach program

A randomized controlled trial of a pediatric asthma outreach program A randomized controlled trial of a pediatric asthma outreach program A randomized controlled trial of a pediatric asthma outreach program Greineder D K, Loane K C, Parks P Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment (...) on the reliability of the study and the conclusions drawn. Health technology An asthma outreach programme (AOP), a team-based, case-management intervention on emergency ward (EW) and hospital use for paediatric patients with asthma in a staff-model health maintenance organisation. The AOP consisted of an experienced allergy nurse, an allergy nurse practitioner, and an allergist who was available for guidance and consultation. The AOP intervention involved providing an education intervention plus long-term follow

1999 NHS Economic Evaluation Database.

1036. The cost-effectiveness of inhaled fluticasone propionate and budesonide in the treatment of asthma in adults and children Full Text available with Trip Pro

-Asthmatic Agents /economics /therapeutic use; Asthma /drug therapy /economics /physiopathology; Budesonide /economics /therapeutic use; Child; Cost-Benefit Analysis; Female; Fluticasone; Humans; Male; Peak Expiratory Flow Rate; Sensitivity and Specificity AccessionNumber 21999001151 Date bibliographic record published 30/11/2001 Date abstract record published 30/11/2001 NHS Economic Evaluation Database (NHS EED) Produced by the Centre for Reviews and Dissemination Copyright © 2019 University of York (...) The cost-effectiveness of inhaled fluticasone propionate and budesonide in the treatment of asthma in adults and children The cost-effectiveness of inhaled fluticasone propionate and budesonide in the treatment of asthma in adults and children The cost-effectiveness of inhaled fluticasone propionate and budesonide in the treatment of asthma in adults and children Barnes N C, Thwaites R M, Price M J Record Status This is a critical abstract of an economic evaluation that meets the criteria

1999 NHS Economic Evaluation Database.

1037. A randomised controlled trial to assess the relative benefits of large volume spacers and nebulisers to treat acute asthma in hospital

A randomised controlled trial to assess the relative benefits of large volume spacers and nebulisers to treat acute asthma in hospital A randomised controlled trial to assess the relative benefits of large volume spacers and nebulisers to treat acute asthma in hospital A randomised controlled trial to assess the relative benefits of large volume spacers and nebulisers to treat acute asthma in hospital Dewar A L, Stewart A, Cogswell J J, Connett G J Record Status This is a critical abstract (...) of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Two health technologies for the treatment of childhood asthma through the administration of beta-2 agonists were considered in the study: a metered dose inhaler and large volume spacer was compared with conventional nebulisers. Type

1999 NHS Economic Evaluation Database.

1038. The cost-effectiveness of strategies to assess gastroesophageal reflux as an exacerbating factor in asthma

and this was reflected in the authors' conclusions. Implications of the study Given that the response to omeprazole 20 mg/day was identified by the model as having the greatest impact on the cost-effective diagnosis of this problem, additional randomised, controlled trials are needed to confirm this asthma response rate in the asthmatic population. Source of funding None stated. Bibliographic details O'Connor J F B, Singer M E, Richter J E. The cost-effectiveness of strategies to assess gastroesophageal reflux (...) The cost-effectiveness of strategies to assess gastroesophageal reflux as an exacerbating factor in asthma The cost-effectiveness of strategies to assess gastroesophageal reflux as an exacerbating factor in asthma The cost-effectiveness of strategies to assess gastroesophageal reflux as an exacerbating factor in asthma O'Connor J F B, Singer M E, Richter J E Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract

1999 NHS Economic Evaluation Database.

1039. Nebulized ipratropium bromide in acute pediatric asthma: Does it reduce hospital admissions among children presenting to the emergency department?

“standard” practice for a sick asthmatic child. x 5 Beveridge, RC, Grunfeld, AF, Hodder, RV et al. CAEP/CTS Asthma Advisory Committee. Guidelines for the emergency management of asthma in adults. Can Med Assoc J . 1996 ; 155 : 25–37 , x 6 National Asthma Education Program: Expert Panel Report II. Guidelines for the Diagnosis and Management of Asthma . : National Institutes of Health , Bethesda, MD ; 1997 Notwithstanding safety issues, you would also be interested in studies that involve multiple dosing (...) Nebulized ipratropium bromide in acute pediatric asthma: Does it reduce hospital admissions among children presenting to the emergency department? Nebulized Ipratropium Bromide in Acute Pediatric Asthma: Does It Reduce Hospital Admissions Among Children Presenting to the Emergency Department? - Annals of Emergency Medicine Email/Username: Password: Remember me Search Terms Search within Search Share this page Access provided by Volume 34, Issue 1, Pages 75–85 Nebulized Ipratropium Bromide

1999 Evidence-Based Emergency Medicine

1040. Other drugs for severe asthma and unconventional therapies

in asthma, 79 patients with asthma of variable severity, some of whom required glucocorticosteroids, were treated with gold salts or placebo for 30 weeks: 71% of those in the treated group improved compared with only 44% of the control group. A 22-week, double-blind study compared intramuscular gold therapy with placebo in 9 asthmatic patients requiring high doses of prednisone. While on gold therapy, 5 of the patients reduced their need for glucocorticosteroid; 2 had to stop gold therapy because (...) followed 28 asthmatic adult patients requiring at least 2.5 mg of prednisone daily (mean 7.6 ± 5.3 mg) for 26 weeks. Auranofin significantly reduced glucocorticosteroid use by 4 mg/d (versus 0.3 mg/d in the placebo group), asthma symptoms and exacerbations and improved FEV 1 . In a recent, large 6-month double-blind placebo-controlled multicentre study, all patients were severely asthmatic, were taking low-dose inhaled glucocorticosteroids and required at least 10 mg of prednisone daily for at least 3

1999 CPG Infobase